Characterization of comorbid conditions burdening hidradenitis suppurativa: a multicentric observational study.
CONCLUSIONS: HS is associated with a variety of comorbid conditions that should be considered to perform targeted routine screening and to improve HS management. PMID: 30295448 [PubMed - as supplied by publisher]
Authors: Bergland OU, Søraas CL, Larstorp ACK, Halvorsen LV, Hjørnholm U, Hoffman P, Høieggen A, Fadl Elmula FEM Abstract PURPOSE: The blood pressure (BP) lowering effect of renal sympathetic denervation (RDN) in treatment-resistant hypertension shows variation amongst the existing randomised studies. The long-term efficacy and safety of RDN require further investigation. For the first time, we report BP changes and safety up to 7 years after RDN, compared to drug adjustment in the randomised Oslo RDN study. MATERIALS AND METHODS: Patients with treatment-resistant hypertension, defined...
Authors: Zhang W, Xu JZ, Lu XH, Li H, Wang D, Wang JG Abstract PURPOSE: We hypothesise that dietary sodium intake interacts with serum uric acid to influence blood pressure (BP) in children and adolescents. In the present study, we investigated ambulatory BP in relation to hyperuricaemia, dietary sodium intake and their interaction in children and adolescents with hypertension. MATERIALS AND METHODS: A total of 616 study participants were 10-24 years old and had primary hypertension diagnosed after admission in a specialised inpatient ward. Ambulatory BP monitoring was performed during hospitalisat...
Publication date: Available online 9 October 2020Source: Clinical Plasma MedicineAuthor(s): Dr. Arisi Mariachiara, Venturuzzo Anna, Gelmetti Alessandra, Guasco Pisani Edoardo, Bassissi Stefania, Rossi Mariateresa, Calzavara-Pinton Piergiacomo
CONCLUSION: The proposed PHARMAC criteria will give access to these important drugs to those people with T2DM who will likely benefit the most. PMID: 33032305 [PubMed - in process]
Authors: Siamashvili M, Davis S Abstract INTRODUCTION: Bromocriptine mesylate quick release (QR) is a dopamine D2 receptor agonist and is the only oral, primarily centrally acting drug that can be used for the treatment of adults with type 2 diabetes. AREAS COVERED: The authors describe current recommendations on the use of bromocriptine mesylate QR. Major efficacy and safety parameters of the late phase trials, including The Cycloset Safety Trial, have been identified and presented. EXPERT OPINION: Efficacy of bromocriptine mesylate QR monotherapy appears to be low but is compensated by favorable safety pr...
Publication date: Available online 10 October 2020Source: Nutrition, Metabolism and Cardiovascular DiseasesAuthor(s): Naila Choudhary, Katia Bravo-Jaimes, Carmen Smotherman, Saadia Sherazi, Dale F. Kraemer, Gladys P. Velarde
Publication date: Available online 9 October 2020Source: Nutrition, Metabolism and Cardiovascular DiseasesAuthor(s): Vanda Craveiro, Elisabete Ramos, Joana Araújo
Publication date: December 2020Source: Journal of Functional Foods, Volume 75Author(s): Tingting Wang, Lin Zheng, Tiantian Zhao, Qi Zhang, Zhitong Liu, Xiaoling Liu, Mouming Zhao
Publication date: Available online 10 October 2020Source: Brain, Behavior, and ImmunityAuthor(s): Irene Esteban-Cornejo, Chelsea M. Stillman, Maria Rodriguez-Ayllon, Arthur F. Kramer, Charles H. Hillman, Andrés Catena, Kirk I. Erickson, Francisco B. Ortega
TYPE 2 diabetes may feel like a minefield - can you eat this or that without spiking blood sugar levels? If you're feeling peckish, what's a good, healthy option for lunch?
More News: Acne | Crohn's Disease | Databases & Libraries | Dermatology | Diabetes | Eating Disorders & Weight Management | Endocrinology | Hidradenitis | Hypertension | Inflammatory Bowel Disease | Metabolic Syndrome | Obesity | Oranges | Ovaries | Polycystic Ovary Syndrome | Skin | Study | Thyroid